Drugs / PSI-352938
PSI-352938
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01497327 | Jul 2011 → Jan 2012 | hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01435044 | Sep 2011 → Apr 2013 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PSI-352938 | “GS-0938 (PSI-352938) alone and in combination” NCT01435044 ↗ |
| Known as | GS-0938 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01435044 ↗ |
| Known as | PSI-938 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2160007 ↗ |
| Modality | Small molecule | — CHEMBL2160007 ↗ |
| Route | Oral | “administered orally once daily” NCT01435044 ↗ |